Viking Global Investors and Marshall Wace led a $75m funding round in Areteia Therapeutics.

Investment firms Viking Global Investors and Marshall Wace led a $75m funding round in Areteia Therapeutics, a clinical stage biotechnology company, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners. The additional capital raised will fund significant expansion of the ongoing Phase III program, to include adding clinical development in Japan along with several additional global markets, expansion of manufacturing activities and additional life-cycle management including development of a once daily formulation.